This summer, venture investment trends have given the medical diagnostics industry reason for at least a little optimism.
Roche's Ventana Medical Systems is linking up with Arizona State University to launch a diagnostics-focused master's degree professional program at the school.
Cambridge, U.K.-based Lab21, which focuses on personalized medicine and clinical diagnostics, plans to become a subsidiary of Paris-based Novacyt, which makes cytology diagnostic tests and tools for various cancers.
FDA officials approved the Georgia company's gene-based test to determine red blood cell types during transfusions.
Seattle's Adaptive Biotechnologies has pulled in $105 million from Viking Global Investors to finish off combined Series C and D rounds. The cash infusion will expand the commercial reach of the company's immunosequencing tech to help diagnose and treat cancer, infectious diseases and autoimmune disorders.
Maryland's Diagnostic Biochips is pursuing a $1.5 million round of angel funding to advance development of a microchip brain implant that would be more precise than an MRI in gathering diagnostic data and less invasive than a blood test.
Two of the biggest players in Brazil's diagnostics industry are likely to confront major changes in the coming months--both worth noting as global competitors seek to enter one of the largest emerging markets around.
ResearchDx, one of the few outfits devoted to contract test making, has extended its operation to include the Middle East, a region the company said is home to a growing biotech market.
Starting this January, FierceBiomarkers is merging with its sister publication, FierceDiagnostics. FierceDiagnostics will retain its name and brand, but coverage will expand to include the use of biomarkers as they relate to the broader diagnostics industry.
Hologic now has a fresh CEO and two added board members, thanks to the machinations of activist investor Carl Icahn. But the new leader of the Massachusetts company known for women-focused diagnostic medical imaging and surgical products insists growth is a much bigger priority over a sale, at least for now.